Shots:

• The first patient has been dosed in P-l/ll adaptive-design study assessing the safety- tolerability- pharmacokinetics- and antitumor activity of LNS8801+ Keytruda (pembrolizumab) in patients who had previous clinical benefit from immune checkpoint inhibitors and then subsequently progressed
• The initiation of the study follows the identification of the RP2D in the ongoing study of LNS8801. The company anticipates opening several more phase 2 dose-expansion cohorts exploring LNS8801 activity as a monothx. and in combination with other compounds in 2021
• LNS8801 (PO) is a bioavailable small molecule that is a highly specific and potent agonist of the GPER and has demonstrated target engagement and clinical benefit in advanced cancer patients. P-l/ll study’s results are anticipated to be presented in a peer-reviewed setting in 2021
  
   Ref: PRNewswire | Image: PRNewswire